A study conducted at The Department of Urology, Yokosuka Kyosai Hospital, Japan, evaluated the efficacy and safety of using a low-dose chemotherapy combination of docetaxel, estramustine and dexamethasone in men with castrate resistant prostate cancer (CRPC). The study enrolled sixty-nine with CRPC. Docetaxel dosage was downed to 25 mg/m2 on days 1 and 8 every [...]
There remain for many people questions about Provenge. The most common question I hear is about the financial cost of the treatment for what has been described as “only 4 months of life extension for $93,000, is it worth it?” Well, the answer is a clear yes! […]
More news from the AACR Annual Meeting Cruciferous vegetables, we all know them and some of us love them. What we know is that they need to form a part of the standard prostate cancer diet, but some early research shows that a substance found in the them can make prostate cancer cells even more [...]
The continuing search for effective treatments for men with hormone refractory prostate cancer (HRPC) has been a long and not very successful story. To date, under scientific conditions, the only chemotherapy which has demonstrated any survival benefit for men with prostate cancer has been docetaxel with prednisone. However, the survival benefit is very limited, only [...]
Thanks to Kathy Meade, I just viewed an exceptional video about advanced prostate cancer. It also includes information on bone health, screening, research, the need for funding and the history of prostate cancer treatment. All advocates and men with prostate cancer should learn something by watching the video. The following is the link: http://www.itvisus.com/programs/hbhm/index.asp#ooid=Iza2VhMTqn-tHgaxfstDRMBJ 1b12EW7i [...]